Certara initiated with a Neutral at UBS

UBS initiated coverage of Certara with a Neutral rating and $17 price target. The company’s return to double-digit sales growth will likely be elongated due to biopharma end market headwinds, the analyst tells investors in a research note. The firm expects ongoing cost-cutting initiatives from large pharma customers and funding concerns afflicting smaller customers will pressure the company’s near-term growth.